HomeCompareSELB vs QSR

SELB vs QSR: Dividend Comparison 2026

SELB yields 226.96% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SELB wins by $252.99M in total portfolio value
10 years
SELB
SELB
● Live price
226.96%
Share price
$0.88
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$253.01M
Annual income
$135,537,151.87
Full SELB calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.76
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$387.88
Full QSR calculator →

Portfolio growth — SELB vs QSR

📍 SELB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSELBQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SELB + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SELB pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SELB
Annual income on $10K today (after 15% tax)
$19,291.87/yr
After 10yr DRIP, annual income (after tax)
$115,206,579.09/yr
QSR
Annual income on $10K today (after 15% tax)
$289.25/yr
After 10yr DRIP, annual income (after tax)
$329.70/yr
At 15% tax rate, SELB beats the other by $115,206,249.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SELB + QSR for your $10,000?

SELB: 50%QSR: 50%
100% QSR50/50100% SELB
Portfolio after 10yr
$126.52M
Annual income
$67,768,769.87/yr
Blended yield
53.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

SELB
Analyst Ratings
10
Buy
1
Hold
Consensus: Buy
Altman Z
-3.6
Piotroski
3/9
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.6% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SELB buys
0
QSR buys
0
No recent congressional trades found for SELB or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSELBQSR
Forward yield226.96%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$253.01M$24.7K
Annual income after 10y$135,537,151.87$387.88
Total dividends collected$240.02M$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock
Analyst consensusBuyBuy

Year-by-year: SELB vs QSR ($10,000, DRIP)

YearSELB PortfolioSELB Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$33,396$22,696.32$11,038$337.57+$22.4KSELB
2$106,573$70,838.67$12,156$345.43+$94.4KSELB
3$325,301$211,268.16$13,359$352.69+$311.9KSELB
4$950,756$602,683.85$14,654$359.36+$936.1KSELB
5$2,663,535$1,646,225.90$16,045$365.45+$2.65MSELB
6$7,160,158$4,310,175.78$17,539$370.97+$7.14MSELB
7$18,490,047$10,828,678.09$19,143$375.96+$18.47MSELB
8$45,918,422$26,134,071.85$20,863$380.42+$45.90MSELB
9$109,788,499$60,655,787.13$22,708$384.39+$109.77MSELB
10$253,010,846$135,537,151.87$24,685$387.88+$252.99MSELB

SELB vs QSR: Complete Analysis 2026

SELBStock

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Full SELB Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this SELB vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SELB vs SCHDSELB vs JEPISELB vs OSELB vs KOSELB vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.